FDA Approves RAS Inhibitor Daraxonrasib for Pancreatic Cancer

The FDA has approved daraxonrasib, the first RAS-targeted therapy for metastatic pancreatic ductal adenocarcinoma in adults who have had prior systemic therapy or are unsuitable for multiagent therapy, based on phase 3 trial results showing nearly doubled overall survival.

This Wire brief sits within Fusion42's coverage of Biotech, and 20 sources have reported it.